A practical reference on bremelanotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-27 and is reviewed periodically as new material appears.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
== Draw Down and Redeployment == On 12 February 2026, it was announced that the USS Gerald R. Ford Carrier Strike Group 12 would be redeployed to support the USS Abraham Lincoln (CVN-72) Carrier Strike Group 3 in the 2026 United States military buildup in the Middle East. However while the U.S. was drawing down its forces in the area, the operation continued, as the U.S. conducted a strike on an alleged drug traffickers vessel in the Caribbean the next day on 13 February killing 3.
== Scope and definitions == There are numerous classes of natural products for which total synthesis is applied to. These include (but are not limited to): terpenes, alkaloids, polyketides. and polyethers. Total synthesis targets are sometimes referred to by their organismal origin such as plant, marine, and fungal. The term total synthesis is less frequently but still accurately applied to the synthesis of natural polypeptides and polynucleotides. The peptide hormones oxytocin and vasopressin were isolated and their total syntheses first reported in 1954. It is not uncommon for natural product targets to feature multiple structural components of several natural product classes.
== History == 3-HO-PCP was mentioned by a chemist under the pseudonym "John Q. Beagle" in 1999 in a post on The Hive. The psychoactive effects of 3-HO-PCP have been described by Bluelight users even before its availability as a research chemical in 2009.
Monoamine oxidases MAO-A and MAO-B play vital roles in the degradation and inactivation of monoamine neurotransmitters such as serotonin and epinephrine. Monoamine oxidases are important drug targets, targeted by MAO inhibitors (MAOIs) such as selegiline. Glutamate dehydrogenase play an important role in oxidative deamination.
In 1974, Prince George's County became the nation's largest school district mandated to implement a busing plan to address segregation. Despite the county's over 80% white demographic at the time, specific communities near Washington, D.C. had denser black populations. Although school boundaries were based on communities, the NAACP contended they mirrored segregated housing patterns. Consequently, a federal court mandated a school busing plan. A 1974 Gallup poll indicated that 75% of the county opposed forced busing, with just 32% of black respondents in favor. The court-mandated busing commenced abruptly mid-school year, excluding final-year high school students. This swift transition disturbed regular school activities and affected family life due to altered schedules, transportation challenges, and disrupted extracurriculars. By 2001, the court concluded that segregation had been sufficiently addressed. The busing order ended, and neighborhood-centric school boundaries were reinstated.
Sources: en.wikipedia.org
=== Multisignature wallet === In contrast to simple cryptocurrency wallets requiring just one party to sign a transaction, multi-sig wallets require multiple parties to sign a transaction. Multisignature wallets are designed to increase security by requiring a predefined threshold of signatures from independent private keys to authorize any transaction.
== Etymology == The name Kuril originates from the autonym that the Indigenous Ainu had used for the islands, kur, meaning 'man'. It may also be related to names for other islands that have traditionally been inhabited by the Ainu people, such as Kuyi or Kuye for Sakhalin and Kai for Hokkaido. In Japanese, the Kuril Islands are known as the Chishima Islands (Kanji: 千島列島, Chishima Rettō, lit. 'Thousand-Island Archipelago'), and also as the Kuriru Islands (Katakana and Kanji: クリル列島, Kuriru Rettō). Once Russians had discovered the islands in the 18th century, they derived a name for islands from the Russian kurit′ курить 'to smoke' due to the perpetual volcanic plumes emitting from the islands' volcanoes resembling smoke.
== Personal life == Lowrie’s adolescence was spent in Boulder, Colorado, where he attended various high schools briefly before joining the United States Navy. He first met his wife Ellen McLain in 1984 in Arnhem, Netherlands, during the European tour of Show Boat, which McLain starred in. They returned to the United States, where they married and moved in together, initially in New York City. They then spent two years in Indiana, before they finally settled in Seattle to pursue acting. Lowrie has since voiced characters alongside McLain in Team Fortress 2, Half-Life 2, and Dota 2.
The world's largest producers of ethylene oxide are Dow Chemical Company (3–3.5 Mt (3.3–3.9 million short tons) in 2006), Saudi Basic Industries (2,000–2,500 tonnes (2,200–2,800 short tons) in 2006), Royal Dutch Shell (1.328 Mt (1.464 million short tons) in 2008–2009), BASF (1.175 Mt (1.295 million short tons) in 2008–2009), China Petrochemical Corporation (~1 Mt (1.1 million short tons) in 2006), Formosa Plastics (~1 Mt (1.1 million short tons) in 2006), and Ineos (0.92 Mt (1.01 million short tons) in 2008–2009).
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.